{
    "Trade/Device Name(s)": [
        "LIAISON Anti-HAV",
        "LIAISON XS"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K223403",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210272"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOL",
        "JJF"
    ],
    "Summary Letter Date": "November 8, 2022",
    "Summary Letter Received Date": "November 9, 2022",
    "Submission Date": "December 8, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.3310",
        "21 CFR 862.2170"
    ],
    "Regulation Name(s)": [
        "Hepatitis A Virus (HAV) Serological Assays",
        "Analyzer, Chemistry, Micro, For Clinical Use"
    ],
    "Analyte Class(es)": [
        "serology",
        "microbiology",
        "chemistry"
    ],
    "Analyte(s)": [
        "Total antibodies to hepatitis A (anti-HAV)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Sodium heparin plasma"
    ],
    "Specimen Container(s)": [
        "Primary tube",
        "Aliquot tube",
        "Pediatric tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON Analyzer family",
        "LIAISON XS Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Automated immunoassay",
        "Magnetic particle technology"
    ],
    "Methodologies": [
        "Competitive sandwich chemiluminescence immunoassay",
        "Qualitative serological testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "System",
        "Reagent",
        "Consumable",
        "Cleaning solution",
        "Buffer",
        "Tube",
        "Container"
    ],
    "Document Summary": "FDA 510(k) summary for LIAISON Anti-HAV assay and LIAISON XS Analyzer for qualitative detection of total anti-HAV antibodies using automated chemiluminescent immunoassay technology.",
    "Indications for Use Summary": "Intended for qualitative detection of total antibodies to hepatitis A (anti-HAV) in human serum and sodium heparin plasma samples, as an aid in laboratory diagnosis of current or previous HAV infection and to determine antibody response in vaccine recipients; not for blood/tissue donor screening.",
    "fda_folder": "Microbiology"
}